Home » Michael Rogawski » OB Pharmaceuticals announces the appointment of Dr. Michael Rogawski

OB Pharmaceuticals announces the appointment of Dr. Michael Rogawski

posted in: Michael Rogawski 0

LONDON, ONTARIO June 12, 2020 — OB Pharmaceuticals announces the appointment of Dr. Michael Rogawski to Chief Scientific Advisor and Chair of its Scientific and Clinical Advisory Board. Dr. Rogawski, a professor of neurology and pharmacology at the University of California, Davis School of Medicine, is an internationally recognized expert on antiseizure medications and drug discovery and development for epilepsy. He teaches in the UC Davis School of Medicine, is on the active medical staff of UC Davis Health, and was formerly chair of the Neurology Department there.
“I am delighted to assist OB Pharmaceuticals in bringing transformational therapies for epilepsy to patients,” said Dr. Rogawski. “OB has a unique discovery platform that has successfully identified a differentiated class of molecules with the potential to prevent seizures in individuals suffering from epilepsy who are resistant to current treatments.”
Before UC Davis, Dr. Rogawski was senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke (NIH-NINDS).
“Having known Mike back from our days at NIH together, I am confident he will provide the level of guidance going forward to ensure our success as we move TD567 through late preclinical and into the regulatory process and clinical development,” remarked Dr. Larry Mahan, CEO. “I look forward to working closely with him.”
Dr. Rogawski graduated from Amherst College with a B.A. in biophysics and from Yale University with an M.D. and Ph.D. in pharmacology. After serving as a postdoctoral fellow in the Laboratory of Neurophysiology, NINDS, he completed residency training in neurology at Johns Hopkins. He has served on the board of directors of the American Epilepsy Society and as an advisor to the NIH and the Food and Drug Administration in the U.S.
“We are pleased and excited to welcome Mike into an expanded role with the company. He brings an uncommon combination of high-level scientific and clinical expertise along with advanced corporate development abilities” commented John Poulter, Chairman. “He is well versed in our science and will strongly complement the expertise of Larry Mahan, our CEO, in filling the role left vacant with last year’s passing of my brother and co-founder Mike.”


About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals with epilepsy through the development of first-in-class therapies that prevent seizures without side effects.

Leave a Reply

Your email address will not be published. Required fields are marked *